Halocort

Quick links to important sections

Halocort

Method of action: Very Strong

Treatment option: Plaque Psoriasis, Psoriasis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Halocort

What is Halocort? (Ulobetasol Propionate)

Property Description
Active Ingredient Ulobetasol (Halobetasol Propionate)
Form Cream, Ointment, Lotion, Foam
Pharmacological Class Corticosteroid (Super-high potency, Class I)
Route of Administration Topical (applied to the skin)
Origin Synthetic Glucocorticoid

What Type of Medicine is Halocort?

Halocort is a prescription-only medication that is classified as a super-high potency synthetic corticosteroid intended for topical dermatological use. Its identity is centered on the active component, Halobetasol Propionate, which is also referred to by the non-proprietary synonym Ulobetasol. This compound functions as a powerful glucocorticoid receptor agonist. This high-strength compound, being manufactured, is structurally distinct from naturally occurring adrenal hormones, affording it the efficacy that places it in the highest-potency category of topical corticosteroids.

Active Ingredient and Available Forms

The therapeutic action of Halocort is delivered entirely by its single-ingredient product, Ulobetasol. This medication is available in several dosage forms optimized for targeted application, including a cream, an ointment, a lotion, and a specialized foam. These various topical preparations—including the heavy, occlusive ointment and the lighter, quick-absorbing cream—are designed to deliver the potent agent across diverse affected skin regions. This range of vehicles allows for the application method to be tailored to specific skin types and lesion characteristics.

General Purpose of This Topical Glucocorticoid

The core therapeutic role of this super-high potency agent is to provide rapid and decisive relief from pronounced inflammatory and pruritic manifestations affecting the skin. Halobetasol Propionate is utilized for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. This is achieved through its strong anti-inflammatory action and antipruritic effect, which help to mitigate physical signs of distress, such as redness and swelling, along with the sensation of severe itching.

Regulatory References

  1. Halobetasol Propionate Mechanism of Action
  2. NIH/DailyMed
  3. FDA/DailyMed

What side effects are possible with Halocort?

Possible Side Effects and Safety Information

The safety profile of Halocort (Halobetasol Propionate), a super-high potency topical corticosteroid, is structured around local skin reactions and the potential for systemic effects due to absorption. Adverse events are officially classified based on the frequency observed in clinical trials, adhering to regulatory standards.

Officially Documented Adverse Reactions

Adverse reactions primarily affect the skin and subcutaneous tissue. The official regulatory documents classify the following reactions based on their frequency:

Classification Adverse Reaction(s) System-Organ Class
Common (Reported ge 1%) Burning Skin and Subcutaneous Tissue Disorders
Uncommon (Reported < 1%) Stinging, Folliculitis Skin and Subcutaneous Tissue Disorders

Systemic and Serious Adverse Reactions

Since Halobetasol Propionate is a potent corticosteroid, significant systemic absorption can occur, leading to serious adverse reactions related to Endocrine and Metabolic disorders. The primary serious safety concerns documented in regulatory information include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and Cushing's Syndrome. These conditions result from hypercortisolism due to high levels of the absorbed medication.

Safety Constraints and Population-Specific Notes

The risk of both local effects (such as skin atrophy) and systemic effects increases with prolonged use and the application of occlusive dressings, as noted in the regulatory documents. Systemic absorption may also produce metabolic changes, including hyperglycemia and glucosuria.

Pediatric patients are officially noted as a sensitive population. They may exhibit greater susceptibility to HPA axis suppression and Cushing's Syndrome due to their larger skin surface area to body weight ratio, increasing systemic exposure. The label also notes the risk of growth retardation, delayed weight gain, and intracranial hypertension in this group.

This safety structure ensures comprehensive communication of both the frequent, local events and the clinically significant, systemic risks associated with this high-potency medicine.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Halocort (Halobetasol Propionate) overdose centers on the risk of systemic absorption of the super-high potency compound. Excessive absorption can lead to measurable Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which is the primary documented presentation of overdose. Clinical signs may include manifestations consistent with Cushing’s syndrome, along with laboratory findings of hyperglycemia and glucosuria.


Severe Outcomes and Emergency Action

Severe or life-threatening outcomes documented in the regulatory labeling include the potential for adrenal insufficiency, particularly upon withdrawal of the product. In the pediatric population, there is a noted greater risk of systemic toxicity, including the development of adrenal insufficiency and intracranial hypertension.

Immediate medical help must be sought for any case of accidental ingestion of Halocort. Management of documented systemic toxicity is symptomatic and supportive; it may involve utilizing a less potent corticosteroid and requires periodic evaluation for HPA axis suppression, often using the ACTH stimulation test. If adrenal insufficiency is confirmed, supplemental systemic corticosteroids may be required as part of the management protocol.

Therapeutic Uses of Halocort

What Halocort Treats: Main Uses and Benefits

Halocort is a relevant option in clinical settings that involve acute or unstable symptom patterns, where short-term symptomatic assistance is commonly needed. The medication is relevant for managing groups of symptoms that may appear abruptly, including those related to physical discomfort, systemic imbalance, or inflammatory states associated with acute episodes.

This application is relevant across conditions characterized by periods of heightened symptoms or episodic manifestations. It offers support for symptom clusters that lead to noticeable functional strain, helping to manage symptoms that become more disruptive during flare-ups and assisting during difficult episodes.

This symptomatic support may assist with maintaining functional stability when symptoms are more noticeable, as the treatment:

“provides support that helps ease the overall symptom burden.”


Quick Fact: Supports Relief from Symptoms that Interfere with Daily Functioning

Eligibility and Restrictions for Use

Halocort (Halobetasol Propionate) is a super-high potency topical corticosteroid. Eligibility for use is strictly defined by regulatory guidelines due to the potential for systemic effects like suppression of the hypothalamic-pituitary-adrenal (HPA) axis.

Contraindications and Restrictions

Classification Population/Condition
Contraindicated Patients with known hypersensitivity (allergy) to Halobetasol Propionate or any other component in the formulation.
Not Recommended Pediatric patients under 12 years of age (safety and effectiveness not established, higher risk of systemic toxicity).
Absolute Restriction Rosacea or perioral dermatitis.
Application Site Restriction Face, groin, axillae (underarms), or areas under occlusive dressings (unless directed by a physician).
Special Caution Pregnancy (Category C - use only if potential benefit justifies potential risk to the fetus) and Lactation (caution advised, unknown if detectable amounts pass into human milk).

For eligible adults, use is typically limited to two consecutive weeks and the total weekly dosage should not exceed 50 grams to minimize the risk of systemic absorption. Geriatric patients are generally eligible but may require caution as they can be more sensitive to treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Halocort (Ulobetasol Propionate) focuses on two primary interaction patterns related to its potent corticosteroid class and topical route of administration. These patterns revolve around the risk of increased systemic exposure and resulting pharmacodynamic effects.

Documented Interaction Profile

Category Officially Documented Interaction Status
Drug–Drug Metabolic Interactions No specific interactions involving CYP enzymes or drug transporters are explicitly documented in regulatory labels.
Pharmacodynamic Interactions Co-administration with other corticosteroid-containing products (topical or systemic) poses a risk of additive systemic glucocorticoid effects.
Exposure-Modifying Factors Use under occlusive dressings is officially noted to enhance percutaneous absorption, resulting in a clinically relevant increase in systemic exposure.

This additive risk is officially described as increasing the potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and the manifestations of Cushing’s syndrome.

Population-Specific Cautions

Official labeling contains a specific note regarding the pediatric population: children may be more susceptible to systemic toxicity (including HPA axis suppression) due to a higher ratio of skin surface area to body mass. This physiological factor amplifies the severity of any potential absorption-related systemic effects. No specific interactions with food, alcohol, or herbal products are formally documented.

Mechanism of Action

How Halocort Works

Halocort (halobetasol propionate) is a synthetic corticosteroid that exerts its effects by modulating core cellular processes involved in physiological responses. Its mechanism relies on three distinct domains of action.

First, the compound acts as a transcription factor by binding to intracellular glucocorticoid receptors. This ligand-receptor complex translocates to the cell nucleus, where it regulates gene expression: it upregulates the production of specific proteins, notably Lipocortin-1, and downregulates the synthesis of certain signaling mediators.

Second, the resulting increase in Lipocortin-1 acts to inhibit the enzyme Phospholipase A2 (PLA2). This step blocks the release of arachidonic acid from membrane phospholipids, thereby preventing the initiation of the arachidonic acid cascade and the subsequent generation of signaling molecules like prostaglandins and leukotrienes.

Third, the mechanism includes direct influence on local microcirculation. Halocort initiates vasoconstriction and modifies capillary permeability. This action helps limit the extravasation of fluid and cells from blood vessels into the surrounding tissue, contributing to changes in localized fluid dynamics and coloration.

Dosage and Administration Information

How to use Halocort

Halocort (Halobetasol Propionate) is a super-high potency corticosteroid whose administration follows established protocols to ensure proper use, focusing on dosage, frequency, and application method.


Administration Scope and Dosage

Category Administration Guideline
Route of Administration Topical (applied to the skin) only; it is not for use in the eyes, mouth, or vagina.
Dosing Schedule A thin layer is to be applied to the affected areas.
Maximum Dose Total weekly use should not exceed 50 grams of the product, regardless of the formulation used.
Frequency The 0.05% cream, ointment, foam, and lotion are typically applied twice daily. The 0.01% lotion is applied once daily

Procedural and Time Constraints

The usage protocol emphasizes a limited duration of application, reflecting the medication’s high strength. Treatment with the 0.05% formulations is usually limited to two consecutive weeks. If the condition is under control before this period ends, the medication should be discontinued. The 0.01% lotion, used for specific conditions, may be used for a longer course, typically up to eight weeks.

Administration involves applying the medication and rubbing it in gently and completely. For certain formulations, such as the foam or lotion, the container must be shaken prior to use. The medication is typically not applied to the face, groin, or axillae (armpits), and the treated skin area should not be covered with bandages or occlusive dressings unless advised by a healthcare professional. Use of this medication is not recommended for children under 12 years of age.

Recent Clinical Evidence

Halocort: Overview of Studies for Plaque Psoriasis

Research exploring short-term symptom changes for this combination treatment has focused primarily on Randomized, Double-Blind, Vehicle-Controlled Clinical Trials (RCTs). These studies, typically lasting up to eight weeks, was studied for adult patients with moderate-to-severe plaque psoriasis. These trials are designed to compare the effects observed with the active treatment against the effects of applying only the inactive lotion base, known as the "vehicle."

Studies reported that the longest research monitored the maintenance of low disease activity over 52 weeks. These studies reported findings related to the Body Surface Area (BSA) over the course of the year when the treatment was applied intermittently. Regarding potential systemic exposure, a small subset of studies evaluated cortisol levels to monitor physiological changes. Long-term effects for this specific physiological monitoring are not fully established.

Strength and Limitations of Available Research

The foundational evidence for this treatment was evaluated in several large, controlled Phase 3 Randomized Trials (RCTs). These trials were conducted to explore short-term symptom changes under controlled conditions. The studies used a vehicle control, allowing researchers to explore patterns observed with the treatment against a non-active base. The trials were also double-blind, a design used to minimize potential bias in how symptoms are measured.

While research provides insight into short-term changes, there are still areas where the evidence is limited. Comparative evidence is lacking as the primary trials did not evaluate the treatment directly against other common active topical treatments. Furthermore, long-term effects are not fully established, as most controlled studies had follow-up durations limited to eight weeks. Data for certain groups, such as children under 18 or pregnant individuals, remain insufficient.

Key Studies & References

  1. Efficacy and safety of halobetasol propionate 0.01% and tazarotene 0.045% lotion in plaque psoriasis: a 52-week, open-label, safety study

Frequently Asked Questions (FAQ)

Common questions about Halocort (FAQ)

Q: How quickly should I expect to see results from Halocort?

A: Studies and official information indicate that if the condition does not improve, the diagnosis should be re-evaluated within two weeks. This suggests that some therapeutic response to the medication is expected within this initial time frame. Patients should always refer to the specific instructions provided by their healthcare provider.

Q: What's the difference between Halocort and over-the-counter creams?

A: Halocort (Halobetasol Propionate) is classified as a super-high potency corticosteroid, meaning it is classified as a medication of the highest topical potency. Unlike over-the-counter creams, it is a prescription-only medication and is intended for use on conditions that require a powerful anti-inflammatory effect.

Q: Does Halocort treat the symptoms or the underlying cause?

A: According to the official product information, Halocort is indicated for the relief of the inflammatory and pruritic manifestations (symptoms) of corticosteroid-responsive skin conditions. Its mechanism of action primarily involves reducing these symptoms, such as inflammation and itching.

Q: Is Halocort safe for long-term use?

A: Due to its super-high potency, official guidelines recommend limiting treatment with the 0.05% formulations to no more than two consecutive weeks, and the total dose used per week should not exceed 50 grams. This limitation is a safety measure to minimize the potential risk of the drug being absorbed into the body and causing systemic effects like suppression of the HPA axis.

Q: Are there any signs that a Halocort side effect is serious?

A: Serious systemic adverse reactions noted in regulatory documents can include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression or Cushing's syndrome. Signs of systemic absorption may also include metabolic changes like hyperglycemia (high blood sugar) and glucosuria.

Q: Does alcohol consumption affect how Halocort works?

A: No specific interactions between Halocort and food, alcohol, or herbal products are formally documented in the official regulatory labeling. Patients with concerns about consuming alcohol during treatment may wish to consult their healthcare provider.

Q: Why do some people say Halocort stops working after a while?

A: Regulatory guidelines stress that the medication should be discontinued once the skin condition is controlled, and clinical studies have examined intermittent use to maintain effectiveness over time. This controlled application pattern is a recognized strategy intended to prevent the potential development of tolerance, or tachyphylaxis, to the medication.

Q: Can I apply makeup or other cosmetic products over Halocort?

A: Official patient instructions strictly advise that the treated skin area should not be covered with bandages or occlusive (airtight) dressings unless specifically directed by a physician. The official guidance cautions against covering the area excessively, which is a consideration when applying cosmetic products.

Q: How does Halocort compare to other high-potency topical steroids?

A: Halocort is classified as a super-high potency topical corticosteroid (Class I), placing it in the strongest potency category. It is utilized for its strong anti-inflammatory and anti-itch effects, and its high potency is the reason for the controlled limits on dosage and duration.

Q: What is the potential for rebound flare-ups after discontinuing Halocort?

A: Official regulatory documents emphasize the importance of limiting the duration of application and discontinuing the drug when control is achieved. This is a critical safety measure intended to prevent the worsening of the condition, or a 'rebound' effect, which is a phenomenon associated with stopping potent topical steroids.

Q: Is it necessary to use a moisturizer with Halocort?

A: The official product information does not mandate or prohibit the use of a moisturizer alongside Halocort. However, it is essential to follow the strict advice against using any kind of occlusive (airtight) dressing or bandage over the treated area unless directed by a healthcare provider.

Q: Is it normal to feel a slight burning sensation when first applying Halocort?

A: Yes, regulatory documents list a burning sensation as a common adverse reaction that was reported in clinical trials. Severe or persistent burning, or the presence of other side effects, should be discussed with a healthcare provider.

Q: Is a prescription always needed to get Halocort?

A: Yes, Halocort (Halobetasol Propionate) is classified as a prescription-only medication ('Rx Only'). It is not available for purchase over-the-counter and requires authorization from a licensed healthcare provider.

Q: What are some common reasons a doctor might prescribe Halocort?

A: Halocort is primarily prescribed for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. This includes conditions such as moderate to severe plaque psoriasis and certain types of chronic eczema.

Q: Why is it advised to wash hands after applying Halocort?

A: Patient instructions in the official product information advise washing hands after applying the product, unless the hands are the area being treated. This is a standard safety measure to prevent unintended exposure, absorption, or transfer of the potent medication to other areas of the body, such as the face or eyes.

Q: What kind of specialist typically prescribes Halocort?

A: As a potent topical dermatological medication, Halocort is most commonly prescribed by specialists who manage skin conditions, such as dermatologists. The medication is intended to be used only as directed by a qualified physician.

Q: Can Halocort be used to treat fungal infections?

A: Official regulatory documents advise that if a skin infection, such as a fungal infection, is present, an appropriate anti-fungal or anti-bacterial agent should be used. If the infection does not clear up promptly, the regulatory guidance is that use of the corticosteroid should be discontinued until the infection is controlled.

Q: Can Halocort cause an increase in acne?

A: Yes, official safety information indicates that acneiform eruptions (a type of acne-like breakout) are listed among the local adverse reactions that have been reported with the use of topical corticosteroids.

Q: Does Halocort have any known drug interactions with common cold or flu medicines?

A: The official regulatory labels do not document specific metabolic interactions with common over-the-counter cold or flu medications. The main drug interaction risk involves the co-administration of other steroid-containing products, which increases the risk of systemic effects.

Q: Is Halocort safe for people with liver or kidney problems?

A: The risk of systemic effects, such as HPA axis suppression, is known to be increased by factors that raise overall systemic exposure. Regulatory documents specifically note that this risk can be elevated in patients with compromised skin barriers or those with liver failure.

Q: Are there any long-term studies on the safety of Halocort?

A: While controlled trials for the high-potency formulations are typically limited to two consecutive weeks, some clinical studies involving the 0.01% lotion formulation were conducted over a longer duration, up to 52 weeks, to assess the long-term maintenance of low disease activity.

How should Halocort be stored and disposed of?

How to Store and Dispose of Halobetasol Propionate (Halocort)

Halobetasol Propionate must be stored at Controlled Room Temperature, specifically 20 C to 25 C ( 68 F to 77 F), with permitted short excursions. It is essential to keep the medicine from freezing and to store it away from excess heat and moisture.

The medication should be kept in its original container, tightly closed, and stored out of the sight and reach of children.

For the topical foam, the pressurized canister must be protected from high temperatures and should not be exposed to heat above 49 C ( 120 F); do not puncture or incinerate the canister. Expired or unused Halobetasol Propionate must be disposed of in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Halocort found in:

A-Z Index: